



from [Neurotune AG](#) and [NiKem Research srl](#)

Neurotune AG and NiKem Research Srl enter into a Research Service Agreement

Schlieren and Baranzate, April 2nd, 2007.

Neurotune and NiKem Research announced that the two companies have signed a 12 months Research Service Agreement on February 1st, 2007.

Under the terms of the agreement, NiKem Research will make its integrated platform available to Neurotune, including medicinal, parallel and analytical chemistry, exploratory ADMET profiling and in vivo PK. The collaboration aims to design, synthesize and optimize compounds against Neurotune proprietary target neurotrypsin.

Financial terms of the agreement were not disclosed.

In collaborating with NiKem Research, Neurotune adds to its own expertise the knowledge and the technologies for the fast optimization of meaningful leads.

NiKem Research understands that biology-oriented, innovation rich young Biotech companies represent a significant market opportunity for integrated, medchem-driven drug discovery CROs. NiKem Research is flexible enough to accommodate the project needs and the financial constraints of small Biotechs, and is committed to deliver high quality preclinical candidates. In particular, NiKem Research is delighted to work with Neurotune on an exciting and innovative project, and looks forward to a long and fruitful collaboration between the two companies.

About Neurotune AG

Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.

Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy - Sarcopenia, second priority to drugs for rehabilitation therapies after stroke or traumatic brain injury, and third priority is given to drugs for treatment of other CNS disturbances.

About NiKem Research srl

NiKem Research is a spin-off from the former SmithKline Beecham Research Centre in Milan, Italy. NiKem Research provides innovative solutions to many of the challenges of drug discovery, being an international leader in Lead Discovery and Optimization. NiKem Research focuses on fully developing and exploiting its core competencies - from medicinal to computational chemistry, from explorative ADMET profiling to in vivo PK. This platform and knowledge is aiming to identify better medicines faster for NiKem's clients.

About Sarcopenia

With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy –Sarcopenia - is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.

The treatment of Sarcopenia is a growing market with no available causal treatment.

Contact:

Mrs. Theres Oesch
Assistant to the CEO
neurotune ag
Wagistrasse 27
8952 Schlieren (Zurich)
Switzerland
URL www.neurotune.com
Phone +41 44 200 21 95
Fax +41 44 200 20 10
theres.oesch@neurotune.com

Mrs. Samadhi Battistoni
Assistant to the CEO
NiKem Research srl
Via Zambelletti 25
20021 Baranzate (Milan)
Italy
URL www.nikemresearch.com
Phone +39 02 35694 7428
Fax +39 02 35694 7606
samadhi.battistoni@nikemresearch.com